Recruiting

Redifferentiating Medications

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT05733013

Conditions

Thyroid Cancer

Thyroid

Refractory Thyroid Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Surveillance Visit

Study Details

Brief summary:

The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.

Conditions

Thyroid Cancer

Thyroid

Refractory Thyroid Cancer

Study ID

NCT05733013

Start date

Feb 7, 2023

Status verified date

Apr, 2026

Completion date

Feb 7, 2028

Anticipated

Primary completion date

Feb 7, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients ≥ 18 years old at time of consent

Inclusion Criteria:

  • Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI.
  • Patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care.
  • Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and/or therapeutic radioactive iodine administration.
  • Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and/or therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent.

Exclusion Criteria:

  • RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and/or therapeutic use of radioactive iodine as part of a prospective clinical trial.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants with refractory thyroid cancer patients

Interventions

Surveillance Visit

Follow-up visits will be carried out at intervals per usual clinical practice. Tolerance of medication and adverse events will be recorded in every visit.

Primary outcome measure

  • Adverse events will be collected in every visit [ Time Frame: 2 years ]

Central Contacts and Locations

Central contacts

Laura Boucai, MD

646-608-3906boucail@mskcc.org

Alan Ho, MD, PhD

646-608-3774hoa@mskcc.org

Locations

Memorial Sloan Kettering Cancer Center

Recruiting

New York, New York, United States, 10065

Contacts

Laura Boucai, PhD

646-608-3906

More Information

Sponsor

Memorial Sloan Kettering Cancer Center

Last update posted

Apr 27, 2026

Last verified

Apr, 2026

Keywords

  • RAI refractory thyroid cancer
  • thyroid cancer
  • thyroid
  • Refractory Thyroid Cancer
  • Radio-iodine refractory thyroid cancer
  • 22-320
  • Memorial Sloan Kettering Cancer Center

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2026-04-27.